These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25901825)

  • 1. A protein-targeting strategy used to develop a selective inhibitor of the E17K point mutation in the PH domain of Akt1.
    Deyle KM; Farrow B; Qiao Hee Y; Work J; Wong M; Lai B; Umeda A; Millward SW; Nag A; Das S; Heath JR
    Nat Chem; 2015 May; 7(5):455-62. PubMed ID: 25901825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain.
    Landgraf KE; Pilling C; Falke JJ
    Biochemistry; 2008 Nov; 47(47):12260-9. PubMed ID: 18954143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A computational approach for investigating the mutational landscape of RAC-alpha serine/threonine-protein kinase (AKT1) and screening inhibitors against the oncogenic E17K mutation causing breast cancer.
    Thirumal Kumar D; Jain N; Evangeline J; Kamaraj B; Siva R; Zayed H; George Priya Doss C
    Comput Biol Med; 2019 Dec; 115():103513. PubMed ID: 31698236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.
    Carpten JD; Faber AL; Horn C; Donoho GP; Briggs SL; Robbins CM; Hostetter G; Boguslawski S; Moses TY; Savage S; Uhlik M; Lin A; Du J; Qian YW; Zeckner DJ; Tucker-Kellogg G; Touchman J; Patel K; Mousses S; Bittner M; Schevitz R; Lai MH; Blanchard KL; Thomas JE
    Nature; 2007 Jul; 448(7152):439-44. PubMed ID: 17611497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung.
    Malanga D; Scrima M; De Marco C; Fabiani F; De Rosa N; De Gisi S; Malara N; Savino R; Rocco G; Chiappetta G; Franco R; Tirino V; Pirozzi G; Viglietto G
    Cell Cycle; 2008 Mar; 7(5):665-9. PubMed ID: 18256540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells.
    Guo G; Qiu X; Wang S; Chen Y; Rothman PB; Wang Z; Chen Y; Wang G; Chen JL
    Oncogene; 2010 Jul; 29(26):3845-53. PubMed ID: 20440266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The GRP1 PH domain, like the AKT1 PH domain, possesses a sentry glutamate residue essential for specific targeting to plasma membrane PI(3,4,5)P(3).
    Pilling C; Landgraf KE; Falke JJ
    Biochemistry; 2011 Nov; 50(45):9845-56. PubMed ID: 21932773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.
    Shoji K; Oda K; Nakagawa S; Hosokawa S; Nagae G; Uehara Y; Sone K; Miyamoto Y; Hiraike H; Hiraike-Wada O; Nei T; Kawana K; Kuramoto H; Aburatani H; Yano T; Taketani Y
    Br J Cancer; 2009 Jul; 101(1):145-8. PubMed ID: 19491896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer associated E17K mutation causes rapid conformational drift in AKT1 pleckstrin homology (PH) domain.
    Kumar A; Purohit R
    PLoS One; 2013; 8(5):e64364. PubMed ID: 23741320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
    Hechtman JF; Sadowska J; Huse JT; Borsu L; Yaeger R; Shia J; Vakiani E; Ladanyi M; Arcila ME
    Mol Cancer Res; 2015 Jun; 13(6):1003-8. PubMed ID: 25714871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma.
    Cohen Y; Shalmon B; Korach J; Barshack I; Fridman E; Rechavi G
    Gynecol Oncol; 2010 Jan; 116(1):88-91. PubMed ID: 19853286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AKT Inhibition in Solid Tumors With AKT1 Mutations.
    Hyman DM; Smyth LM; Donoghue MTA; Westin SN; Bedard PL; Dean EJ; Bando H; El-Khoueiry AB; Pérez-Fidalgo JA; Mita A; Schellens JHM; Chang MT; Reichel JB; Bouvier N; Selcuklu SD; Soumerai TE; Torrisi J; Erinjeri JP; Ambrose H; Barrett JC; Dougherty B; Foxley A; Lindemann JPO; McEwen R; Pass M; Schiavon G; Berger MF; Chandarlapaty S; Solit DB; Banerji U; Baselga J; Taylor BS
    J Clin Oncol; 2017 Jul; 35(20):2251-2259. PubMed ID: 28489509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias.
    Mahmoud IS; Sughayer MA; Mohammad HA; Awidi AS; EL-Khateeb MS; Ismail SI
    Br J Cancer; 2008 Aug; 99(3):488-90. PubMed ID: 18665177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AKT1 E17 K pleckstrin homology domain mutation in urothelial carcinoma.
    Zilberman DE; Cohen Y; Amariglio N; Fridman E; Ramon J; Rechavi G
    Cancer Genet Cytogenet; 2009 May; 191(1):34-7. PubMed ID: 19389506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis.
    Mancini ML; Lien EC; Toker A
    Oncotarget; 2016 Apr; 7(14):17301-13. PubMed ID: 27004402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A gain of function mutation in AKT1 increases hexokinase 2 and diminishes oxidative stress in meningioma.
    Singh S; Lathoria K; Umdor SB; Singh J; Suri V; Sen E
    Cytokine; 2024 Apr; 176():156535. PubMed ID: 38325141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AKT1(E17K) in human solid tumours.
    Bleeker FE; Felicioni L; Buttitta F; Lamba S; Cardone L; Rodolfo M; Scarpa A; Leenstra S; Frattini M; Barbareschi M; Grammastro MD; Sciarrotta MG; Zanon C; Marchetti A; Bardelli A
    Oncogene; 2008 Sep; 27(42):5648-50. PubMed ID: 18504432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.
    Askham JM; Platt F; Chambers PA; Snowden H; Taylor CF; Knowles MA
    Oncogene; 2010 Jan; 29(1):150-5. PubMed ID: 19802009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic myeloid leukemia and BCR/ABL signal pathways are not associated with AKT1 pleckstrin homology domain (E17K) mutations.
    He Y; Zheng J; Hu Y; Xiao H; Liu J; Li X; Du W; Chen X; Hu Y; Huang S
    Eur J Haematol; 2010 Jan; 84(1):87-8. PubMed ID: 19744127
    [No Abstract]   [Full Text] [Related]  

  • 20. A Hot-spot of In-frame Duplications Activates the Oncoprotein AKT1 in Juvenile Granulosa Cell Tumors.
    Bessière L; Todeschini AL; Auguste A; Sarnacki S; Flatters D; Legois B; Sultan C; Kalfa N; Galmiche L; Veitia RA
    EBioMedicine; 2015 May; 2(5):421-31. PubMed ID: 26137586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.